Phase 4
Completed N=71
The Use of Belladonna and Opium Suppository in the Treatment of Postoperative Stent Pain
Source: ClinicalTrials.gov NCT03332056 ↗Enrolled (actual)
71
Serious AEs
0.0%
Results posted
Jun 2023
Primary outcomePrimary: Global Quality of Life Score on Postoperative Day 1 — 4.4; 5.4 score on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to determine if preemptive B&O suppository placement will decrease post-operative pain in patients undergoing ureteral stent placement.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Global Quality of Life Score on Postoperative Day 1 |
4.4; 5.4 | — |
| PRIMARY Global Quality of Life Score on Postoperative 3 |
4.5; 5.6 | — |
| SECONDARY Number of Participants With Postoperative Complications as a Result of the Use of B&O Suppository |
— | — |
| SECONDARY Number of Participants With Unanticipated Postoperative Visits |
3; 5 | — |
| SECONDARY Measurement of Post-operative Narcotic Use |
55; 65 | — |
Eligibility Criteria
Inclusion Criteria
- patients who will receive ureteroscopy with concurrent placement of a ureteral stent.
Exclusion Criteria
- age < 18,
- neurologic deficits of any kind
- non-English speaking patients.
Data sourced from ClinicalTrials.gov (NCT03332056). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.